# Safety, Tolerability, and Dose Response of VNA-318 in Healthy Males

> **NCT06721091** · PHASE1 · COMPLETED · sponsor: **VANDRIA** · enrollment: 92 (actual)

## Conditions studied

- Healthy Volunteer

## Interventions

- **DRUG:** VNA-318
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06721091
- **Lead sponsor:** VANDRIA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-03
- **Primary completion:** 2025-11-27
- **Final completion:** 2025-11-27
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06721091

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06721091, "Safety, Tolerability, and Dose Response of VNA-318 in Healthy Males". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06721091. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*